Axon Enterprise, Inc. (NASDAQ:AXON) Stock Holdings Lowered by Beese Fulmer Investment Management Inc.

Beese Fulmer Investment Management Inc. lowered its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 0.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,141 shares of the biotechnology company’s stock after selling 35 shares during the quarter. Beese Fulmer Investment Management Inc.’s holdings in Axon Enterprise were worth $1,655,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Axon Enterprise by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock worth $2,547,878,000 after purchasing an additional 212,401 shares during the period. Motley Fool Asset Management LLC lifted its holdings in Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after acquiring an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. lifted its holdings in Axon Enterprise by 44.0% in the 2nd quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock valued at $110,546,000 after acquiring an additional 114,800 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Axon Enterprise by 13.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock valued at $108,496,000 after acquiring an additional 45,049 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in Axon Enterprise by 1.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 270,430 shares of the biotechnology company’s stock valued at $79,571,000 after acquiring an additional 4,365 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insiders Place Their Bets

In other Axon Enterprise news, Director Matthew R. Mcbrady sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares of the company’s stock, valued at $1,783,916.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Axon Enterprise news, Director Matthew R. Mcbrady sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares of the company’s stock, valued at $1,783,916.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the sale, the director now directly owns 26,259 shares of the company’s stock, valued at $11,500,916.82. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 371,172 shares of company stock valued at $137,000,162 over the last 90 days. 6.10% of the stock is currently owned by company insiders.

Axon Enterprise Trading Down 1.5 %

NASDAQ:AXON opened at $442.69 on Thursday. The stock’s 50 day moving average price is $393.29 and its 200 day moving average price is $334.66. Axon Enterprise, Inc. has a 52 week low of $199.29 and a 52 week high of $455.17. The company has a market capitalization of $33.45 billion, a P/E ratio of 116.81, a P/E/G ratio of 12.05 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. During the same quarter in the prior year, the company posted $0.80 earnings per share. The firm’s revenue was up 34.5% on a year-over-year basis. On average, research analysts forecast that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on AXON shares. Craig Hallum upped their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. JMP Securities upped their price target on shares of Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a report on Wednesday. Robert W. Baird upped their price objective on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Finally, Northland Securities upped their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and an average target price of $382.85.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.